Login
Sanofi (ADR) NASDAQ: SNY
Sanofi SA is a healthcare company focused on patient needs and engaged in the research, development, manufacture and marketing of healthcare products. The Company is organized around three principal activities: Pharmaceuticals, Human Vaccines via Sanofi Pasteur, and Animal Health via Merial
| Name | Sanofi (ADR) |
| Ticker | SNY |
| Exchange | NASDAQ |
| Sector | Health Care |
| Industry | Drug Manufacturers - Diversified |
|
Price
52W Low/High |
50.69
45.30 / 53.77 |
| Momentum | Weak Up |
| Market cap | 127 B |
| 1Y Total Return |
13.69%
Weak |
| 1Y Volatility |
22.58%
Low Risk |
Relative Strength Index : Attempt to identify overbought (above 80) and oversold (below 20) conditions
Sanofi SA is a healthcare company focused on patient needs and engaged in the research, development, manufacture and marketing of healthcare products. The Company is organized around three principal activities: Pharmaceuticals, Human Vaccines via Sanofi Pasteur, and Animal Health via Merial
Details
| Ticker | SNY |
| Name | Sanofi (ADR) |
| ISIN | US80105N1054 |
| CUSIP | |
| Exchange | NASDAQ |
| Sector | Health Care |
| Industry | Drug Manufacturers - Diversified |
| Country | France |
| Currency | U.S. Dollar |
Share as of 4/15/21
| Close Price | 50.69 |
| 52W Low/High | 45.30 / 53.77 |
| Market cap | 127 B |
| 1Y Total Return |
13.69%
Weak |
| 1Y Volatility |
22.58%
Low Risk |
| Beta | 0.27 |
| PE (trailing) |
41.82
Above Average |
| 12M Dividends | 1.890217 |
| Last Dividend Date | 4/30/20 |
| Dividend Yield | 3.73% |
Fin. Strength
| Net Profit Margin | 7.5% |
| Cash from Op. / Cur. Liabilities | 0.38 |
| Diluted Earnings / Share | 1.21 |
| ROE | 4.6% |
| ROIC | 3.8% |
| Price / Revenue | 1.6 |
| Price / Book | 1.0 |
| Price / CF | 7.6 |
| Current Ratio | 1.4 |
| Cur.Liabilities / Tot.Liabilities | 0.4 |
| Financial Leverage | 0.44 |
| in Mils USD |
rolling-year up to December
|
||||||
|---|---|---|---|---|---|---|---|
| Income Statement | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | |
| Revenue |
40,903
|
40,542
|
44,151
|
36,573
|
38,351
|
35,622
|
|
| Gross Profit |
27,886
|
27,548
|
29,991
|
25,296
|
26,339
|
23,988
|
|
| R&D |
6,541
|
6,698
|
6,673
|
5,450
|
5,591
|
5,089
|
|
| EBITDA |
11,784
|
10,797
|
17,393
|
10,811
|
10,815
|
10,488
|
|
| Operating Income |
3,397
|
5,181
|
7,271
|
7,027
|
6,129
|
6,442
|
|
| Net Income exc. Extra |
3,050
|
4,893
|
10,285
|
4,962
|
4,716
|
4,631
|
|
| per Share | |||||||
| Diluted avg Shares |
1,257
|
1,255
|
1,267
|
1,296
|
1,321
|
1,331
|
|
| EPS exc. Extra |
1.21
|
1.95
|
4.06
|
1.91
|
1.79
|
1.74
|
|
| Dividend |
1.89
|
2.04
|
1.29
|
1.72
|
1.78
|
2.01
|
|
| Div. Yield (an.) |
3.44%
|
4.17%
|
2.64%
|
3.68%
|
4.06%
|
4.07%
|
|
| Balance Sheet | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | |
| Total Assets |
122,539
|
126,600
|
121,739
|
110,297
|
112,564
|
102,734
|
|
| Cash, Eq & Invt ShortTerm |
10,247
|
7,869
|
12,579
|
10,825
|
10,186
|
7,974
|
|
| Total Current Assets |
31,099
|
27,931
|
32,137
|
28,121
|
27,424
|
24,712
|
|
| Total Non-Current Assets |
91,440
|
98,669
|
89,602
|
82,176
|
85,141
|
78,022
|
|
| Intangibles |
66,403
|
75,141
|
65,054
|
53,916
|
56,747
|
56,688
|
|
| Total Liabilities |
58,291
|
59,515
|
50,693
|
49,471
|
48,527
|
43,380
|
|
| Total Current Liabilities |
22,153
|
19,745
|
18,850
|
17,317
|
18,509
|
13,747
|
|
| Long Term Debt |
36,138
|
39,769
|
31,843
|
32,154
|
30,018
|
29,633
|
|
| Shareholder equity |
64,059
|
66,905
|
70,840
|
60,647
|
63,860
|
59,198
|
|
| Cash Flow | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | |
| Cash from Operations |
8,417
|
6,303
|
8,999
|
8,624
|
9,813
|
8,112
|
|
| Depreciation |
8,100
|
4,863
|
4,495
|
3,478
|
4,704
|
3,984
|
|
| Cash from Investing |
-1,317
|
-14,620
|
-3,532
|
-2,779
|
-3,583
|
-3,650
|
|
| Capex |
643
|
211
|
1,733
|
1,975
|
2,817
|
1,359
|
|
| Cash from Financing |
-4,558
|
4,470
|
-9,637
|
-4,204
|
-3,961
|
-5,464
|
|
| Stock Issued |
166
|
-1,050
|
-2,248
|
-2,743
|
-1,331
|
-1,181
|
|
| Debt (LT) Issued |
-534
|
9,911
|
-2,801
|
2,416
|
1,481
|
-397
|
|
| Free Cash Flow |
12,622
|
12,429
|
9,254
|
6,381
|
11,411
|
7,413
|
|
| Ratios | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | |
| Net Profit Margin |
7.5%
|
12.1%
|
23.3%
|
13.6%
|
12.3%
|
13.0%
|
|
| NCFO / Op.Income |
247.8%
|
121.7%
|
123.8%
|
122.7%
|
160.1%
|
125.9%
|
|
| Current Ratio |
1.4
|
1.4
|
1.7
|
1.6
|
1.5
|
1.8
|
|
| Financial Leverage D/E |
0.44
|
0.42
|
0.27
|
0.32
|
0.29
|
0.26
|
|
| Return on Capital Avg |
3.8%
|
6.0%
|
10.0%
|
6.6%
|
6.1%
|
5.6%
|
|
| Return on Shareholder Equity |
4.6%
|
7.2%
|
15.7%
|
8.0%
|
7.2%
|
6.7%
|
|
Fundamentals
No documents are available for the moment, please check back soon, or save the asset to be notified when documents are available